Zusammenfassung
Ungefähr die Hälfte aller Patienten mit nichtkleinzelligem Lungenkarzinom entwickelt im Krankheitsverlauf zereabrale Metastasen. Sie stellen eine besondere klinische Herausforderung dar. Weiterentwicklungen im Hinblick auf Resektionsverfahren, Bestrahlungsmodalitäten und neue Substanzen kommen aber auch diesen Patienten zugute.
Literatur
Inno A et al. State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res. 2016;5(6):599–609.
Reinmuth N et al. [Updated Recommendation for Treatment of Metastatic Non-Small Cell Lung Cancer]. Pneumologie. 2018;72(2):138–54.
Wen PY et al. Medical management of patients with brain tumors. J Neurooncol. 2006;80(3):313–32.
Gaspar L et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.
Mulvenna P et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388(10055):2004–14.
Barker FG 2nd. Craniotomy for the resection of metastatic brain tumors in the U.S., 1988-2000: decreasing mortality and the effect of provider caseload. Cancer. 2004;100(5):999–1007.
Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007;12(7):884–98.
Patchell RA et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.
Brown PD et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC•3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049–60.
Mahajan A et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040–8.
Brown PD et al. Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? J Clin Oncol. 2018;36(5):483–91.
Stark AM et al. Surgical treatment for brain metastases: prognostic factors and survival in 177 patients. Neurosurg Rev. 2005;28(2):115–9.
Paek SH et al. Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery. 2005;56(5):1021–34; discussion 1021-34.
Khuntia D et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24(8):1295–304.
Brown PD et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016;316(4):401–9.
Soffietti R et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31(1):65–72.
Chang EL et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037–44.
DeAngelis LM et al. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39(6):789–96.
Sahgal A et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91(4):710–7.
Patchell RA et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280(17):1485–9.
Prokic V et al. Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: a planning study on treatment concepts. Int J Radiat Oncol Biol Phys. 2013;85(1):264–70.
Mittapalli RK et al. Quantitative Fluorescence Microscopy Measures Vascular Pore Size in Primary and Metastatic Brain Tumors. Cancer Res. 2017;77(2):238–46.
Bernardo G et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from nonsmall-cell lung cancer: a phase II study. Cancer Invest. 2002;20(3):293–302.
Minotti V et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer. 1998;20(2):93–8.
Franciosi V et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85(7):1599–605.
Fujita A et al. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology. 2000;59(4):291–5.
Cortes J et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology. 2003;64(1):28–35.
Barlesi F et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;22(11):2466–70.
Dinglin XX et al. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. J Neurooncol. 2013;112(3):461–6.
Moro-Sibilot D et al. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study. Lung Cancer. 2015;90(3):427–32.
Robinet G et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12(1):59–67.
Dempke WC et al. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy? Anticancer Res. 2015;35(11):5797–806.
Broniscer A et al. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res. 2007;13(5):1511–5.
Proto C et al. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from nonsmall cell lung cancer: the present and the future. Transl Lung Cancer Res. 2016;5(6):563–78.
Milton DT et al. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer. 2006;107(5):1034–41.
Wu C et al. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer. 2007;57(3):359–64.
Grommes C et al. „Pulsatile“ high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13(12):1364–9.
Welsh JW et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-smallcell lung cancer. J Clin Oncol. 2013;31(7):895–902.
Hoffknecht P et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10(1):156–63.
Schuler M et al. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016;11(3):380–90.
Soria JC et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113–25.
Solomon BJ et al. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Oncol. 2016;34(24):2858–65.
Costa DB et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015;33(17):1881–8.
De Castro et al. First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4). J Thorac Oncol. 2016;12(1, Suppl):Abstr PL03.07.
Gadgeel SM et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34(34):4079–85.
Peters S et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377:829–838.
Magnuson WJ et al. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. J Clin Oncol. 2017;35(10):1070–7.
Soon YY et al. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis. Radiother Oncol. 2015;114(2):167–72.
Tsakonas G et al. Management of brain metastasized non-small cell lung cancer (NSCLC) — From local treatment to new systemic therapies. Cancer Treat Rev. 2017;54:122–31.
Berghoff AS et al. Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. Am Soc Clin Oncol Educ Book. 2016;35:e116–22.
Rittmeyer A et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65.
Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39.
Author information
Authors and Affiliations
Corresponding author
Additional information
Interessenkonflikt
Prof. Dr. med. Florian Würschmidt gibt folgende potenzielle Interessenkonflikte an: keine. PD Dr. med. Niels Reinmuth gibt folgende potenzielle Interessenkonflikte an: Vortrags und Beratungshonorare von Roche, Lilly, Novartis, MSD Sharp & Dohme, Bristol-Myers Squibb, Takeda, Böhringer-Ingelheim, AstraZeneca, Pfizer. Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.
Rights and permissions
About this article
Cite this article
Reinmuth, N., Würschmidt, F. ZNS-Befall bei Patienten mit NSCLC. Im Focus Onkologie 21, 54–62 (2018). https://doi.org/10.1007/s15015-018-3602-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15015-018-3602-1